| SIG | Lead Contact |
| AI/ML | sam.hadlington@plus-project.co.uk |
| AIMS | Martin.Brown1@thermofisher.com |
| Benefit Risk | shahrul.mt-isa@msd.com; marcoboeri@openhealthgroup.com |
| Biomarkers | nicole_2.kraemer@boehringer-ingelheim.com; guillaume.desachy@pierre-fabre.com |
| Causal Inference | sroels4@its.jnj.com; kelly.vanlancker@ugent.be |
| CMC | kevin.r.lief@gsk.com; Beate Presser |
| CSM/QTL | timothy.e.rolfe@gsk.com; susan.talbot@amgen.com |
| Data Science | julia.chernova@cytel.com; Domingo
Salazar |
| Historical Data | nicky.x.best@gsk.com; simon.wandel@novartis.com |
| HTA | lara.wolfson@msd.com; Anders Gorst-Rasmussen (htasig@psiweb.org) |
| Launch & Lifecycle | jenny.devenport@roche.com; yulia.dyachkova@merckgroup.com |
| Neuroscience-Estimands | paul.delmar@roche.com |
| Oncology Estimands | Oncology estimand working group |
| Openstatsware | alessandro.gasparini@reddooranalytics.se; daniel.sabanes_bove@rconis.com |
| Patient Focused Drug Development (PFDD) | rachael.lawrance@adelphivalues.com; konstantina.skaltsa@iqvia.com |
| Pre-Clinical | eloisa.i.brook@gsk.com |
| Quantitative Decision Making | tguerin@theravance.com; alex.l.carlton@gsk.com |
| Randomisation | johannes.krisam@boehringer-ingelheim.com; annika.scheffold@boehringer-ingelheim.com |
| Real World Data (RWD) | Josephine.Wolfram@astellas.com; rima.izem@novartis.com |
| Regulatory | JHXW@novonordisk.com; christoph.gerlinger@bayer.com |
| Small Populations | tal.x.otiker@gsk.com; aysun.cetinyurek-yavuz@radboudumc.nl |
| Treatment Effect Heterogeneity | david.j.svensson@astrazeneca.com |
| Vaccines | fabian.s.tibaldi@gsk.com |
| Visualisation | kirschbodo@gmail.com |